Britain's competition watchdog has fined Pfizer a record 84.2 million pounds ($107 million) for its role in ramping up the cost of an epilepsy drug by as much as 2,600 percent. » Read More
Jeff Jonas, Sage Therapeutics CEO, discusses his company's new drug to treat postpartum depression and the current drug pricing environment. » Read More
The drug is for the treatment of moderate to severe menapause symptoms like hot flashes and night sweats. » Read More
CNBC's Martin Soong reports on the growth potential of the pharmaceutical industry in India, the largest generic drug producer in the world.
CEO David Schenkein explained that concerns for the molecule were specific to an "extremely high dose, a dose that we would never use in patients."
Incyte president & CEO Herve Hoppenot speaks to CNBC's Meg Tirrell about the growth of bone marrow drug Jakafi, drug pricing under Donald Trump and the company's drug pipeline.
CNBC's Meg Tirrell speaks with Celgene CEO Mark Alles at the American Society of Hematology about the company's immunotherapy partnerships and the upcoming Trump administration.
Looking to improve your overall well-being? These apps can help you keep tabs on your health while reducing stress.
The agency said Friday that it approved a new indication for a drug marketed by Eli Lilly and Boehringer Ingelheim.
Kenneth Frazier, the CEO of pharmaceutical giant Merck, says Trump's call to revamp Obamacare could prove useful.
Researchers have found a functional link between gut bacteria and Parkinson's disease.
Shares of Bluebird were up more than 24 percent in premarket trade Thursday.
CNBC's Meg Tirrell speaks with Express Scripts chief medical officer Dr. Steve Miller about the role of pharmacy benefits managers in drug pricing.
CNBC's Meg Tirrell speaks with Bluebird Bio CEO Nick Leschly about his company's successful study of its multiple myeloma treatment as well as the election effect on the biotech sector.
Three Vancouver companies told CBC Toronto there is a lot of demand from people looking to move away from traditional medicines to cannabis.
Billionaire Steven A. Cohen's former hedge fund SAC Capital Advisors has agreed to pay $135 million to resolve a lawsuit.
The talks with Takeda Pharmaceutical have ended amid a disagreement over the price and other matters, CNBC confirmed.
Mallinckrodt said it experienced "production issues" with a third-party manufacturer supporting its immunotherapy platform, Therakos.
In the likely repeal of the Affordable Care Act, these health-care stocks should perform well, according to some analysts.
Get the best of CNBC in your inbox